MILFORD, Mass. - Waters Corporation (NYSE:WAT) announced today the launch of the Waters TA Instruments Coin Cell Differential Scanning Calorimeter, a device designed for battery safety testing. The $35.7 billion analytical instruments manufacturer has posted 26% revenue growth over the last twelve months, though InvestingPro analysis suggests the stock is currently overvalued relative to its Fair Value estimate.
The instrument enables direct testing of fully assembled coin cells and integrates heat flow, evolved gas, and electrochemical analysis in a single experiment. The system incorporates voltage monitoring and charge/discharge capability, allowing researchers to correlate thermal and electrochemical behavior. It can be coupled with mass spectrometry, Fourier Transform Infrared Spectroscopy, or Gas Chromatography-Mass Spectrometry for off-gas composition analysis.
According to the company’s press release statement, the device features a temperature range from -80°C to 600°C. The capsule design eliminates cell teardown, which the company said reduces average sample preparation time by more than 90% based on an internal study of 12 users.
"Simultaneously capturing thermal, evolved gas, and electrochemical data is not only faster, but also correlates data from the same sample for more exacting insights earlier in development," said Yu Cheng, Vice President of Research and Development and Product Solutions, Materials Sciences at Waters Corporation.
The company stated the Coin Cell DSC is the only commercially available DSC that provides multidimensional data capture for whole-cell thermal testing, based on an internal review of 26 commercially available DSC models as of May 27, 2026.
The system is designed to enable evaluation of coin cells earlier in the development process compared to traditional methods such as accelerating rate calorimetry, which the company said requires large cell formats, specialized facilities, and longer experiment times.
The Waters TA Instruments Coin Cell DSC is available for order, with shipments expected to begin in August 2026. For deeper insights into Waters’ financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro along with additional ProTips for WAT.
In other recent news, Waters Corporation reported first-quarter revenue of $1.27 billion, exceeding analyst projections of $1.20 billion. The company attributed this growth to strong organic performance and contributions from its acquisition of Becton Dickinson assets. Following these results, Waters raised its full-year guidance, indicating confidence in its ongoing business trajectory. Additionally, BofA Securities adjusted its price target for Waters to $370 from $350, maintaining a Neutral rating, while noting the company’s robust quarterly performance. Wolfe Research also initiated coverage on Waters with an Outperform rating, setting a price target of $425. In product development, Waters launched the BioResolve Peptide and GTxResolve Lipid Columns, designed to improve impurity separation in biopharmaceutical products. Furthermore, Waters received FDA clearance for its BD BACTEC FXI Culture System, intended to enhance the detection of bloodstream infections and sepsis. These developments reflect Waters’ active engagement in both product innovation and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for WAT plus thousands of other stocks and find your next hidden gem with massive upside.